Deshpande Pallavi O, Mohan Vishwaraman, Thakurdesai Prasad
Department of Scientific Affairs, Indus Biotech Private Limited, Kondhwa, Pune, Maharashtra, India.
Toxicol Int. 2015 Jan-Apr;22(1):10-20. doi: 10.4103/0971-6580.172251.
Centella asiatica (CA) leaves extract has been shown therapeutic potential. However, safety information is lacking.
To evaluate acute oral toxicity (AOT), sub-chronic toxicity, and mutagenic potential of standardized extract of CA (L.) Urban leaves (INDCA).
For the acute toxicity study, INDCA was orally administered to Sprague-Dawley rats at a dose range of 0-2000 mg/kg. For the repeated dose toxicity study, the rats of either sex were orally administered with INDCA at the doses of 250, 500, and 1000 mg/kg/day for a period of 90 days. The effects on body weight, food and water consumption, organ weight, hematology, clinical chemistry as well as histology were studied. The mutagenic potential of INDCA was tested using reverse mutation assay (Ames test).
Data of each parameter were analyzed by one-way ANOVA followed by Dunnett's test to compare the difference between treated groups.
The administration of INDCA did not produce mortality or significant changes in the clinical signs included but not limited to changes in the skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic and central nervous systems, somatomotor activity, and behavior pattern. The appearance, progress, and disappearance of these signs were recorded. The lethal dose and no observable adverse effect level of INDCA were 2000 mg/kg and 1000 mg/kg, respectively. There were no significant differences in the organ weights, hematological parameters, clinical chemistry values, or gross and microscopic appearance of the organs from the treatment groups as compared to the control group. It was found to be nonmutagenic in reverse mutation assay.
INDCA was found safe in AOT, sub-chronic toxicity, and mutagenicity studies when tested in rats.
积雪草叶提取物已显示出治疗潜力。然而,缺乏安全性信息。
评估积雪草(CA)叶标准化提取物(INDCA)的急性经口毒性(AOT)、亚慢性毒性和致突变潜力。
在急性毒性研究中,将INDCA以0 - 2000 mg/kg的剂量范围经口给予Sprague-Dawley大鼠。在重复剂量毒性研究中,将雌雄大鼠以250、500和1000 mg/kg/天的剂量经口给予INDCA,持续90天。研究其对体重、食物和水消耗、器官重量、血液学、临床化学以及组织学的影响。使用回复突变试验(Ames试验)测试INDCA的致突变潜力。
每个参数的数据通过单因素方差分析,然后进行Dunnett检验以比较各治疗组之间的差异。
给予INDCA未导致死亡,也未在包括但不限于皮肤和毛发、眼睛和黏膜以及呼吸、循环、自主和中枢神经系统、躯体运动活动及行为模式等临床体征上产生显著变化。记录了这些体征的出现、进展和消失情况。INDCA的致死剂量和未观察到不良反应水平分别为2000 mg/kg和1000 mg/kg。与对照组相比,治疗组的器官重量、血液学参数、临床化学值或器官的大体和微观外观均无显著差异。在回复突变试验中发现其无致突变性。
在大鼠试验中,INDCA在急性经口毒性、亚慢性毒性和致突变性研究中被发现是安全的。